Skip to main content

Active COVID-19 Clinical Pathway – All Settings – Anticoagulation

Active COVID-19 Clinical Pathway – All Settings

Anticoagulation

  < 12 yrs ≥ 12 yrs
Inpatient
  • Sequential compression device, if size allows
  • Enoxaparin generally not indicated
  • Discuss with hematology if multiple risk factors for VTE in addition to COVID-19
  • Sequential compression devices, if size allows:
  • and
  • Enoxaparin
    • 0.5 mg/kg/dose subQ q12hr
    • Max initial dose: 60 mg subQ q12hr
    • Goal anti-Xa: 0.2–0.4 units/mL
ICU
  • No Mechanical ventilation or central venous catheter:
    • Sequential compression devices
  • Mechanical ventilation or central venous catheter:
    • Sequential compression devices, if size allows
    • and
    • Enoxaparin
      • < 3 mos: 0.75 mg/kg/dose subQ q12hr
      • ≥ 3 mos: 0.5 mg/kg/dose subQ q12hr
        Max initial dose: 60 mg subQ q12hr
      • Goal anti-Xa: 0.2– 0.4 units/mL
Jump back to top